Fungal Infections in Hematopoietic Stem Cell Transplantation and Solid-Organ Transplantation-Focus on Aspergillosis

Clinics in Chest Medicine

Volumn 30, Issue 2, 2009, Pages 295-306

  Nucci, Marcio ^a   Anaissie, Elias ^b  

^a University Hospital   (Brazil)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Aspergillosis; Fungal infection; Solid organ transplantation; Stem cell transplantation; Transplantation

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; AMPICILLIN; ANIDULAFUNGIN; CASPOFUNGIN; CORTICOSTEROID; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; PIPERACILLIN PLUS TAZOBACTAM; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ASPERGILLOSIS; CANDIDEMIA; CANDIDIASIS; CLINICAL FEATURE; ENGRAFTMENT; FUSARIOSIS; GASTROINTESTINAL DISEASE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; INVASIVE CANDIDIASIS; MICROBIOLOGY; MUCORMYCOSIS; MYCOSIS; ORGAN TRANSPLANTATION; PNEUMONIA; PRIORITY JOURNAL; RADIOLOGY; REVIEW; SEROLOGY;

ASPERGILLOSIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MYCOSES; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS;

EID: 64549129967     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2009.03.001     Document Type: Review

References (77)

1. Wingard J.R. New approaches to invasive fungal infections in acute leukemia and hematopoietic stem cell transplant patients. Best Pract Res Clin Haematol 20 (2007) 99-107
2. Silveira F.P., and Husain S. Fungal infections in solid organ transplantation. Med Mycol 45 (2007) 305-320
3. Marr K.A. Fungal infections in hematopoietic stem cell transplant recipients. Med Mycol 46 (2008) 293-302
4. Nucci M. Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients. Curr Opin Infect Dis 16 (2003) 607-612
5. Abi-Said D., Anaissie E., Uzun O., et al. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 24 (1997) 1122-1128
6. Wingard J.R. The changing face of invasive fungal infections in hematopoietic cell transplant recipients. Curr Opin Oncol 17 (2005) 89-92
7. Thursky K., Byrnes G., Grigg A., et al. Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transplant 34 (2004) 115-121
8. Zaas A.K., Liao G., Chien J.W., et al. Plasminogen alleles influence susceptibility to invasive aspergillosis. PLoS Genet 4 (2008) e1000101
9. Sambatakou H., Pravica V., Hutchinson I.V., et al. Cytokine profiling of pulmonary aspergillosis. Int J Immunogenet 33 (2006) 297-302
10. Sainz J., Perez E., Gomez-Lopera S., et al. IL1 gene cluster polymorphisms and its haplotypes may predict the risk to develop invasive pulmonary aspergillosis and modulate C-reactive protein level. J Clin Immunol 28 (2008) 473-485
11. Granell M., Urbano-Ispizua A., Suarez B., et al. Mannan-binding lectin pathway deficiencies and invasive fungal infections following allogeneic stem cell transplantation. Exp Hematol 34 (2006) 1435-1441
12. Bochud P.Y., Chien J.W., Marr K.A., et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med 359 (2008) 1766-1777
13. Kobayashi R., Kaneda M., Sato T., et al. Evaluation of risk factors for invasive fungal infection after allogeneic stem cell transplantation in pediatric patients. J Pediatr Hematol Oncol 29 (2007) 786-791
14. Pietrangelo A. Iron chelation beyond transfusion iron overload. Am J Hematol 82 (2007) 1142-1146
15. Nucci M., and Anaissie E. Revisiting the source of candidemia: skin or gut?. Clin Infect Dis 33 (2001) 1959-1967
16. Anaissie E.J., Stratton S.L., Dignani M.C., et al. Pathogenic molds (including Aspergillus species) in hospital water distribution systems: a 3-year prospective study and clinical implications for patients with hematologic malignancies. Blood 101 (2003) 2542-2546
17. Morgan J., Wannemuehler K.A., Marr K.A., et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 43 Suppl 1 (2005) S49-S58
18. Wald A., Leisenring W., Van Burik J.A., et al. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 175 (1997) 1459-1466
19. Marr K.A., Carter R.A., Crippa F., et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 34 (2002) 909-917
20. Marr K.A., Carter R.A., Boeckh M., et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 100 (2002) 4358-4366
21. Berenguer J., Allende M.C., Lee J.W., et al. Pathogenesis of pulmonary aspergillosis. Granulocytopenia versus cyclosporine and methylprednisolone-induced immunosuppression. Am J Respir Crit Care Med 152 (1995) 1079-1086
22. Stergiopoulou T., Meletiadis J., Roilides E., et al. Host-dependent patterns of tissue injury in invasive pulmonary aspergillosis. Am J Clin Pathol 127 (2007) 349-355
23. Gerson S.L., Talbot G.H., Lusk E., et al. Invasive pulmonary aspergillosis in adult acute leukemia: clinical clues to its diagnosis. J Clin Oncol 3 (1985) 1109-1116
24. Martino P., Girmenia C., Venditti M., et al. Spontaneous pneumothorax complicating pulmonary mycetoma in patients with acute leukemia. Rev Infect Dis 12 (1990) 611-617
25. Shaukat A., Bakri F., Young P., et al. Invasive filamentous fungal infections in allogeneic hematopoietic stem cell transplant recipients after recovery from neutropenia: clinical, radiologic, and pathologic characteristics. Mycopathologia 159 (2005) 181-188
26. Talbot G.H., Huang A., and Provencher M. Invasive aspergillus rhinosinusitis in patients with acute leukemia. Rev Infect Dis 13 (1991) 219-232
27. Kleinschmidt-DeMasters B.K. Central nervous system aspergillosis: a 20-year retrospective series. Hum Pathol 33 (2002) 116-124
28. Thompson B.H., Stanford W., Galvin J.R., et al. Varied radiologic appearances of pulmonary aspergillosis. Radiographics 15 (1995) 1273-1284
29. Gefter W.B., Albelda S.M., Talbot G.H., et al. Invasive pulmonary aspergillosis and acute leukemia. Limitations in the diagnostic utility of the air crescent sign. Radiology 157 (1985) 605-610
30. Hruban R.H., Meziane M.A., Zerhouni E.A., et al. Radiologic-pathologic correlation of the CT halo sign in invasive pulmonary aspergillosis. J Comput Assist Tomogr 11 (1987) 534-536
31. Chamilos G., Marom E.M., Lewis R.E., et al. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 41 (2005) 60-66
32. Caillot D., Couaillier J.F., Bernard A., et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 19 (2001) 253-259
33. Miceli M.H., Maertens J., Buve K., et al. Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: proof of principle, description, and clinical and research implications. Cancer 110 (2007) 112-120
34. Kojima R., Tateishi U., Kami M., et al. Chest computed tomography of late invasive aspergillosis after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 11 (2005) 506-511
35. Ashdown B.C., Tien R.D., and Felsberg G.J. Aspergillosis of the brain and paranasal sinuses in immunocompromised patients: CT and MR imaging findings. AJR Am J Roentgenol 162 (1994) 155-159
36. De P.B., Walsh T.J., Donnelly J.P., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46 (2008) 1813-1821
37. Maertens J., Theunissen K., Verhoef G., et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 41 (2005) 1242-1250
38. Aquino V.R., Goldani L.Z., and Pasqualotto A.C. Update on the contribution of galactomannan for the diagnosis of invasive aspergillosis. Mycopathologia 163 (2007) 191-202
39. Miceli M.H., Grazziutti M.L., Woods G., et al. Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin Infect Dis 46 (2008) 1412-1422
40. Asano-Mori Y., Kanda Y., Oshima K., et al. False-positive Aspergillus galactomannan antigenaemia after haematopoietic stem cell transplantation. J Antimicrob Chemother 61 (2008) 411-416
41. Ostrosky-Zeichner L., Alexander B.D., Kett D.H., et al. Multicenter clinical evaluation of the (1->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 41 (2005) 654-659
42. Perfect J.R., Cox G.M., Lee J.Y., et al. The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis 33 (2001) 1824-1833
43. Mahfouz T., and Anaissie E. Prevention of fungal infections in the immunocompromised host. Curr Opin Investig Drugs 4 (2003) 974-990
44. Goodman J.L., Winston D.J., Greenfield R.A., et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 326 (1992) 845-851
45. Marr K.A., Crippa F., Leisenring W., et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 103 (2004) 1527-1533
46. Wingard J.R., Carter S.L., Walsh T.J., et al. Results of a randomized, double-blind trial of fluconazole (FLU) vs. voriconazole (VORI) for the prevention of invasive fungal infections (IFI) in 600 allogeneic blood and marrow transplant (BMT) patients. Blood 110 (2007) 163
47. Van Burik J.A., Ratanatharathorn V., Stepan D.E., et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39 (2004) 1407-1416
48. Cornely O.A., Maertens J., Winston D.J., et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356 (2007) 348-359
49. Ullmann A.J., Lipton J.H., Vesole D.H., et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356 (2007) 335-347
50. Glasmacher A., Prentice A., Gorschluter M., et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol 21 (2003) 4615-4626
51. Offner F., Cordonnier C., Ljungman P., et al. Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis 26 (1998) 1098-1103
52. Fukuda T., Boeckh M., Carter R.A., et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 102 (2003) 827-833
53. de F.P., Spagnoli A., Di B.P., et al. Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and/or systemic fungal infection. Bone Marrow Transplant 40 (2007) 245-249
54. Pizzo P.A., Robichaud K.J., Gill F.A., et al. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 72 (1982) 101-111
55. Segal B.H., Almyroudis N.G., Battiwalla M., et al. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis 44 (2007) 402-409
56. Sobel J.D. Design of clinical trials of empiric antifungal therapy in patients with persistent febrile neutropenia: considerations and critiques. Pharmacotherapy 26 (2006) 47S-54S
57. Senn L., Robinson J.O., Schmidt S., et al. 1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis 46 (2008) 878-885
58. Gubbins P.O., Penzak S.R., Polston S., et al. Characterizing and predicting amphotericin B-associated nephrotoxicity in bone marrow or peripheral blood stem cell transplant recipients. Pharmacotherapy 22 (2002) 961-971
59. Pappas P.G., Kauffman C.A., Andes D., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48 (2009) 503-535
60. Marr K.A., Seidel K., White T.C., et al. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 181 (2000) 309-316
61. Nucci M., and Anaissie E. Should vascular catheters be removed from all patients with candidemia? An evidence-based review. Clin Infect Dis 34 (2002) 591-599
62. Herbrecht R., Denning D.W., Patterson T.F., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347 (2002) 408-415
63. Cornely O.A., Maertens J., Bresnik M., et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 44 (2007) 1289-1297
64. Marr K.A., Boeckh M., Carter R.A., et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 39 (2004) 797-802
65. Spellberg B., Edwards Jr. J., and Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 18 (2005) 556-569
66. Van Burik J.A., Hare R.S., Solomon H.F., et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 42 (2006) e61-e65
67. Nucci M., and Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev 20 (2007) 695-704
68. Singh N. Fungal infections in the recipients of solid organ transplantation. Infect Dis Clin North Am 17 (2003) 113-134 viii
69. Singh N., and Paterson D.L. Aspergillus infections in transplant recipients. Clin Microbiol Rev 18 (2005) 44-69
70. Singh N., and Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant 22 (2003) 258-266
71. Gotway M.B., Dawn S.K., Caoili E.M., et al. The radiologic spectrum of pulmonary Aspergillus infections. J Comput Assist Tomogr 26 (2002) 159-173
72. Gordon S.M., and Avery R.K. Aspergillosis in lung transplantation: incidence, risk factors, and prophylactic strategies. Transpl Infect Dis 3 (2001) 161-167
73. Pfeiffer C.D., Fine J.P., and Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 42 (2006) 1417-1427
74. Husain S., Kwak E.J., Obman A., et al. Prospective assessment of Platelia Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients. Am J Transplant 4 (2004) 796-802
75. Kwak E.J., Husain S., Obman A., et al. Efficacy of galactomannan antigen in the Platelia Aspergillus enzyme immunoassay for diagnosis of invasive aspergillosis in liver transplant recipients. J Clin Microbiol 42 (2004) 435-438
76. Fortun J., Martin-Davila P., Alvarez M.E., et al. False-positive results of Aspergillus galactomannan antigenemia in liver transplant recipients. Transplantation 87 (2009) 256-260
77. Drew R.H., Dodds A.E., Benjamin Jr. D.K., et al. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 77 (2004) 232-237